Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)96
Thioredoxin reductase inhibitors: updated patent review (2017-present)44
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)42
Vasopressin receptor antagonists: a patent summary (2018-2022)40
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)36
A patent review of adenosine A2Breceptor antagonists (2016-present)33
Malaria transmission blocking compounds: a patent review32
Antimalarial drugs: what’s new in the patents?29
Exploring drug patent linkage and the first ANDA litigation in China29
Dopamine D3 receptor ligands: a patent review (2014–2020)27
Steroid sulfatase inhibitors: the current landscape27
SUMO-specific protease 1 inhibitors–A literature and patent overview26
Synthetic molecules as DprE1 inhibitors: A patent review25
Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023)25
Mucormycosis medications: a patent review24
Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present)23
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)23
A patent and literature review of CDK12 inhibitors23
Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 – present)23
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)23
A patent review of topoisomerase I inhibitors (2016–present)22
Patent landscape of small molecule inhibitors of METTL3 (2020-present)21
4.071249961853